Fig. 4.

Successful validation of the immunophenotypes in the AHMU‐PC cohort. (A) Heatmap showing the different enrichment of characteristic signatures among immune‐activated, immune‐suppressed, and nonimmune groups; (B) Kaplan–Meier plot showing the recurrence‐free survival outcome in three immunophenotypes; (C) subclass mapping analysis manifested that patients with immune‐activated subtype were more likely to respond to anti‐PD‐1/PD‐L1 treatment (Bonferroni‐corrected P‐value = 0.0399); immunohistochemistry staining and quantification of CD163 (D) and α‐SMA (E) in prostate cancer patients with different immune status (nonimmune, immune‐suppressed, and immune‐activated classes) from AHMU‐PC cohort, Scale bar, 200 μm, 100 μm. t‐Test, Student’s t‐test, K‐W test, Kruskal–Wallis test.